Press release
Hemophilia A Pipeline | Clinical Trials Study Period (2019-2032)| Key Companies - BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi
DelveInsight's, "Hemophilia A -Pipeline Insights, 2023," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download the Sample Report to learn more @https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.
Click here to learn more about the Hemophilia A Market Landscape @https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Key Highlight from Hemophilia A Market Report:
The key Hemophilia A companies working in the treatment landscape include BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi, and many others.
The key Hemophilia A therapies in the pipeline include Concizumab, Fitusiran, BIVV001, Marstacimab, and others.
Hemophilia A Treatment Market
About 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NOVOSEVEN, FEIBA). There are many approved therapies for the management of Hemophilia A which include HEMLIBRA (for both inhibitor and non-inhibitor), SEVENFACT, KOGENATE FS, FEIBA, KOVALTRY, ELOCTATE, NUWIQ, AFSTYLA, and others.
Learn more about the treatment market for Hemophilia A @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Hemophilia A Epidemiology Segmented by:
Hemophilia A Prevalent cases
Hemophilia A Incident Cases
Hemophilia A treatment cases
Hemophilia A Diagnosed cases
Hemophilia A Dug Profile and Companies Covered
BioMarin Pharmaceutical: Concizumab
Roche Pharmaceuticals: Fitusiran
ApcinteX: BIVV001
Novo Nordisk: Marstacimab
Sanofi: Valrox
And many others.
Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Hemophilia A Introduction
Executive Summary of Hemophilia A
Disease Background and Overview
Hemophilia A Epidemiology and Patient Population
Hemophilia A Emerging Therapies
Hemophilia A Market Outlook
Hemophilia A Market Access and Reimbursement of Therapies
Hemophilia A Market Drivers
Hemophilia A Market Barrier
Appendix
Hemophilia A Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the Hemophilia A Market Outlook report @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
DelveInsight Business Research LLP
Aditya Kaul
info@delveinsight.com
https://www.delveinsight.com
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Download the Sample Report to learn more @https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.
Click here to learn more about the Hemophilia A Market Landscape @https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Key Highlight from Hemophilia A Market Report:
The key Hemophilia A companies working in the treatment landscape include BioMarin Pharmaceutical, Roche, ApcinteX, Novo Nordisk, Sanofi, and many others.
The key Hemophilia A therapies in the pipeline include Concizumab, Fitusiran, BIVV001, Marstacimab, and others.
Hemophilia A Treatment Market
About 30% of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NOVOSEVEN, FEIBA). There are many approved therapies for the management of Hemophilia A which include HEMLIBRA (for both inhibitor and non-inhibitor), SEVENFACT, KOGENATE FS, FEIBA, KOVALTRY, ELOCTATE, NUWIQ, AFSTYLA, and others.
Learn more about the treatment market for Hemophilia A @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Hemophilia A Epidemiology Segmented by:
Hemophilia A Prevalent cases
Hemophilia A Incident Cases
Hemophilia A treatment cases
Hemophilia A Diagnosed cases
Hemophilia A Dug Profile and Companies Covered
BioMarin Pharmaceutical: Concizumab
Roche Pharmaceuticals: Fitusiran
ApcinteX: BIVV001
Novo Nordisk: Marstacimab
Sanofi: Valrox
And many others.
Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @
https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Hemophilia A Introduction
Executive Summary of Hemophilia A
Disease Background and Overview
Hemophilia A Epidemiology and Patient Population
Hemophilia A Emerging Therapies
Hemophilia A Market Outlook
Hemophilia A Market Access and Reimbursement of Therapies
Hemophilia A Market Drivers
Hemophilia A Market Barrier
Appendix
Hemophilia A Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the Hemophilia A Market Outlook report @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
DelveInsight Business Research LLP
Aditya Kaul
info@delveinsight.com
https://www.delveinsight.com
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
